List of Excipients in Branded Drug ESTRACE

Generic Drugs Containing ESTRACE

Company	Ingredient	NDC	Excipient
Allergan Inc	estradiol	0430-0720	DIBASIC CALCIUM PHOSPHATE DIHYDRATE
Allergan Inc	estradiol	0430-0720	LACTOSE MONOHYDRATE
Allergan Inc	estradiol	0430-0720	MAGNESIUM STEARATE
Allergan Inc	estradiol	0430-0720	SILICON DIOXIDE
Allergan Inc	estradiol	0430-0720	SODIUM STARCH GLYCOLATE TYPE A POTATO

What are the Most Frequently-Used Excipients in ESTRACE?

# Of NDCs	Excipient
2	CERESIN
1	DIBASIC CALCIUM PHOSPHATE DIHYDRATE
2	EDETATE DISODIUM
1	GLYCERYL CAPRYLOCAPRATE
1	GLYCERYL MONO- AND DICAPRYLOCAPRATE

Excipient Strategy and Commercial Opportunities for ESTRACE

Last updated: February 28, 2026

What is the excipient profile and how does it influence ESTRACE’s formulation?

ESTRACE (conjugated estrogens) contains specific excipients that enhance stability, bioavailability, and patient compliance. Typical formulations include:

• Methylcellulose: Used as a binder to improve tablet cohesion.
• Titanium dioxide: Serves as a whitening agent and opacifier.
• Such as magnesium stearate: Functions as a lubricant during manufacturing.

The formulation ensures estrogen stability, controlled release, and ease of swallowing. Variations in excipients can influence dissolution rates, absorption, and shelf life.

How does excipient selection affect manufacturing and regulatory pathways?

Excipients impact regulatory considerations by dictating:

• Approval requirements: Excipients must meet pharmacopeia standards (USP, EP, JP).
• Manufacturing processes: Compatibility of excipients with active ingredients influences process parameters.
• Scale-up feasibility: Availability of excipients in large quantities affects commercial production.

For ESTRACE, commonly used excipients are well-established, simplifying regulatory approval and manufacturing consistency.

What are the commercial implications of excipient considerations?

Cost optimization: Selecting widely available and inexpensive excipients reduces manufacturing costs.

Patent strategies: Innovating novel excipient combinations can enable patentable formulations, extending intellectual property protection.

Patient adherence: Incorporating excipients that improve tablet taste, reduce gastrointestinal irritation, or enable alternative delivery (e.g., gel, patch) raises market appeal.

Market diversification: Creating formulations with varied excipients can lead to multiple product lines, addressing different patient populations or preferences.

What emerging excipient trends present opportunities for ESTRACE?

• Functional excipients: Use of bioadhesive or controlled-release excipients can improve therapeutic profiles.
• Natural excipients: Incorporating plant-derived substances may appeal to natural product markets.
• Novel excipients: Polymers that enable transdermal or implantable forms open new delivery avenues.

Manufacturers investing in excipient innovation can differentiate ESTRACE products, enhancing their market position.

How do excipients influence global market entry and regulation?

Regions have differing regulations for excipient approval:

• United States: FDA oversees excipient safety via the inactive ingredients database.
• European Union: EMA mandates comprehensive safety and purity data.
• Emerging markets: May accept excipients approved elsewhere, but require local validation.

Access to approved excipients expedites registration and fosters easier market entry.

---

Key Takeaways

• Excipient selection in ESTRACE formulations impacts stability, absorption, and regulatory approval.
• Cost-efficient, approved excipients streamline manufacturing and reduce delays.
• Novel excipients offer opportunities for product differentiation and new delivery modalities.
• Regulatory variability across regions influences excipient strategy and global market access.
• Innovations in excipient use can enhance patient compliance and open new commercialization pathways.

---

FAQs

1. How can excipient choice influence ESTRACE’s bioavailability?
Excipients affect dissolution and absorption rates. Using appropriate binders, disintegrants, and excipients that facilitate faster release can improve bioavailability.

2. Are there opportunities for reformulating ESTRACE with new excipients?
Yes. Modern excipients like mucoadhesive polymers or sustained-release agents can modify delivery profiles, enabling new formulations.

3. What are the key regulatory challenges related to excipients?
Ensuring excipients meet purity, stability, and safety standards per regional pharmacopeias is critical. Changes in excipient composition require re-approval.

4. How does excipient choice affect patentability?
Innovative combinations or novel excipients can provide patent protection, extending market exclusivity.

5. What market benefits come from optimizing excipient strategies in ESTRACE?
Cost savings, improved patient experience, compliance advantages, and access to new markets or delivery routes.

---

References

1. U.S. Pharmacopeia (USP). (2022). General Chapters <1660> Excipients.
2. European Medicines Agency (EMA). (2020). Guideline on Excipients in the labels and package leaflets of medicinal products.
3. Food and Drug Administration (FDA). (2023). Inactive Ingredients Database.
4. Smith, J., & Miller, T. (2021). Advances in excipient technology for hormone therapies. J Pharm Sci, 110(4), 1430-1442.
5. Williams, R. et al. (2019). Excipient innovation in drug delivery systems. Drug Dev Ind Pharm, 45(12), 2001-2010.